CN106456644B - 雄激素合成调节剂 - Google Patents

雄激素合成调节剂 Download PDF

Info

Publication number
CN106456644B
CN106456644B CN201580024124.6A CN201580024124A CN106456644B CN 106456644 B CN106456644 B CN 106456644B CN 201580024124 A CN201580024124 A CN 201580024124A CN 106456644 B CN106456644 B CN 106456644B
Authority
CN
China
Prior art keywords
day
acid
disclosed
conjugated
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580024124.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456644A (zh
Inventor
苏珊妮·简·迪利
格雷戈里·艾伦·斯托洛弗
保罗·克里斯多佛·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tangent Reprofiling Ltd
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of CN106456644A publication Critical patent/CN106456644A/zh
Application granted granted Critical
Publication of CN106456644B publication Critical patent/CN106456644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580024124.6A 2014-05-09 2015-05-11 雄激素合成调节剂 Active CN106456644B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990800P 2014-05-09 2014-05-09
US61/990,800 2014-05-09
PCT/EP2015/060388 WO2015169971A1 (en) 2014-05-09 2015-05-11 Modulators of androgen synthesis

Publications (2)

Publication Number Publication Date
CN106456644A CN106456644A (zh) 2017-02-22
CN106456644B true CN106456644B (zh) 2021-06-15

Family

ID=53269444

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580024124.6A Active CN106456644B (zh) 2014-05-09 2015-05-11 雄激素合成调节剂

Country Status (8)

Country Link
EP (1) EP3139923B1 (enExample)
JP (1) JP6730194B2 (enExample)
CN (1) CN106456644B (enExample)
AU (3) AU2015257594A1 (enExample)
CA (1) CA2950800C (enExample)
ES (1) ES2970762T3 (enExample)
NZ (1) NZ726050A (enExample)
WO (1) WO2015169971A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211868A1 (en) 2012-09-26 2016-06-03 Tangent Reprofiling Limited Modulators of androgen synthesis
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
JP2020516283A (ja) 2017-04-11 2020-06-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN112020556A (zh) 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法
US11957687B2 (en) 2019-07-02 2024-04-16 Regeneron Pharmaceuticals, Inc. Modulators of HSD17B13 and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319950B1 (en) * 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
WO2014049071A1 (en) * 2012-09-26 2014-04-03 Tangent Reprofiling Limited Modulators of androgen synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231190B2 (en) * 2000-12-23 2005-11-03 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
WO2012129673A1 (en) * 2011-03-25 2012-10-04 Universite Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
US9375433B2 (en) * 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319950B1 (en) * 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
WO2014049071A1 (en) * 2012-09-26 2014-04-03 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
JP2017514816A (ja) 2017-06-08
CN106456644A (zh) 2017-02-22
WO2015169971A1 (en) 2015-11-12
NZ726050A (en) 2018-04-27
CA2950800C (en) 2023-01-10
CA2950800A1 (en) 2015-11-12
AU2018203135A1 (en) 2018-05-24
AU2019279922A1 (en) 2020-01-16
JP6730194B2 (ja) 2020-07-29
ES2970762T3 (es) 2024-05-30
EP3139923A1 (en) 2017-03-15
EP3139923B1 (en) 2023-09-27
AU2015257594A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
US10111877B2 (en) Modulators of androgen synthesis
JP6734346B2 (ja) アンドロゲン合成モジュレーター
EP3139923B1 (en) Composition for treating pancreatic adenocarcinoma
JP5525447B2 (ja) Ｐａｒｐ阻害剤としてのキノリノン誘導体
JP2017514816A5 (enExample)
KR20230084163A (ko) 항체-약물 접합체와 parp1 선택적 억제제의 조합
WO2022261643A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
Gras Niraparib hidrochloride
HK1240924B (en) A deuterated triazolopyridazine as a kinase modulator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant